We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Mayo Clinic

Poster Abstracts - PATIENT REPORTED OUTCOMES/QUALITY OF LIFE

RALTAN Study: Risk Assessment for acquired transthyretin Amyloid Neuropathyin Domino Liver Transplantation recipients PC28 (#144)

Daily life in patients with hereditary transthyretin amyloidosis: a qualitative study. PC29 (#1)

Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)

Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)

Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)

Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)

Clinicopathological analyses of ATTRv amyloidosis after liver transplantation with cardiogenic cerebral embolism and subarachnoid hemorrhage PC34 (#89)

Exercise Rehabilitation in Patients with Cardiac Amyloidosis, a Case study PC35 (#101)

Health-related quality of life in hereditary transthyretin amyloidosis, a cross-sectional study PC36 (#106)

Health-related quality-of-life, diagnosis and treatment experiences of AL amyloidosis patients PC37 (#165)

Disease Burden of ATTR Amyloidosis Based on the SF-36v2® Health Survey PC38 (#214)

A Platform for Federated Acquisition of Health-related Quality of Life Data in Systemic Amyloidosis PC39 (#251)

The prevalence of frailty and association with disease severity in transthyretin amyloid cardiomyopathy PC40 (#265)

Health-related Quality of Life as a predictor of Heart Failure Admission and Death in Patients with Amyloidosis PC41 (#284)

Quality of Life of Patients with Variant and Wild-Type Transthyretin Amyloidosis PC42 (#316)

Prevalence and outcome of coronary artery disease in cardiac amyloidosis: A retrospective Austrian multicenter study PC44 (#356)

Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial PC43 (#346)

 Social Determinants of Health-Related Disparities in the Diagnosis of Transthyretin Cardiac Amyloidosis PC45 (#369)

Experiences and benefits of setting up an Amyloidosis patient panel within an early phase clinical trials unit PC46 (#375)

Psychometric Validation of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire PC47 (#507)

Best Practices and Key Barriers for Amyloidosis Patient Care – a Representative Analysis of Multidisciplinary Amyloidosis Specialists, Referring Physicians, Patients, and Patient Advocacy Groups at US Specialized Amyloidosis Centers  PC48 (#509)

Bortezomib Induced Ocular Toxicities in AL Amyloidosis PC49 (#521)